Science
Maker of PRIMA, a CE marked implant restoring central vision in geographic atrophy.
The call
Science has a CE marked implant with published results but no paying patients yet, leaving reimbursement and adoption as the open question.
Science developed PRIMA, a brain implant that helps blind people see again. The company has government approval in Europe and published results in a major medical journal, which takes years for competitors like Medtronic to match, and AI companies like Merge Labs are building different types of brain devices that work differently. The real question is not whether the technology works, but whether hospitals and insurance companies in Europe and America will actually pay for it and patients will choose it, since other approved vision implants from companies like Pixium Vision failed in the marketplace despite working fine.
Why
01
AI pressure: None apparent. No AI product yet substitutes for an implanted retinal device restoring central vision to blind patients. Could AI do the core job? Unlikely.
02
Bigger players: Medtronic (via Precision Neuroscience partnership) and OpenAI backed Merge Labs. Bigger players are assembling brain interface programs that could eventually crowd Science's platform ambitions beyond PRIMA. Could a giant copy it? No, they are blocked.
03
What protects it. CE marking, NEJM published trial data, and acquired Pixium IP give PRIMA a regulatory and clinical record rivals cannot copy quickly.
What would change this call
First commercial PRIMA implant performed in Germany. Shows PRIMA is moving from CE marking to real-world paying patients.
Germany, France, or UK issue formal PRIMA reimbursement decisions within 12 months. Determines whether PRIMA becomes revenue-generating or stalls like Pixium Vision.
Science announces a Series D or reports implant volume/unit economics on first 50 patients. Indicates whether commercial ramp validates the moat or the company needs rescue funding.
Germany, France, or UK issue formal PRIMA reimbursement decisions within 12 months. Determines whether PRIMA becomes revenue-generating or stalls like Pixium Vision.
Science announces a Series D or reports implant volume/unit economics on first 50 patients. Indicates whether commercial ramp validates the moat or the company needs rescue funding.
Key numbers
- $230M Series C raised, $1.5B post-money valuation
- PRIMA trial: 38 patients, 17 sites, 5 countries
- ~150 employees, zero commercial revenue reported
Named risks
- Zero commercial revenue as of July 2026 despite CE marking, reimbursement pathway unproven.
- Sector graveyard precedent: Second Sight and Pixium Vision both had approved retinal implants and still failed commercially.
- US FDA approval timeline for PRIMA remains unconfirmed despite Breakthrough and HUD designations.
- Crowded, better-funded BCI competitive field including Neuralink and OpenAI-backed Merge Labs.
- Biohybrid sensor platform unproven in humans, first trial only optimistically targeted for 2027.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Neuralink | gaining on | 20+ N1 implants and $9.7B valuation reported by mid-2026, vs Science's $1.5B |
| Synchron | contesting | $200M Series D closed Nov 2025, named TIME100 Most Influential Companies 2026 |
| Precision Neuroscience (Medtronic partnership) | contesting | FDA 510(k) clearance April 2025, Medtronic partnership announced Jan 2026 |
| Merge Labs (OpenAI backed) | gaining on | Launched Jan 2026 with ~$250M seed for non-surgical ultrasound BCI |
| Apple | contesting | Announced BCI Human Interface Device input protocol May 2025 |
| Paradromics | contesting | Cleared to start US speech-restoration trial as of July 2026 |
Questions people ask
- Is Science Corporation profitable in 2026?
- No. As of July 22, 2026, Science has zero reported commercial revenue. Its PRIMA retinal implant just received CE marking for sale across 30 European countries, with the first commercial implant in Germany still pending at that date.
- What does Science Corporation's PRIMA device actually do?
- PRIMA is a subretinal photovoltaic implant paired with camera glasses that project near-infrared light onto retinal neurons, restoring functional central vision to patients with geographic atrophy from age-related macular degeneration, per NEJM-published trial data covering 38 patients across 17 sites in five countries.
- Who is Science Corporation's biggest competitor in brain-computer interfaces?
- Neuralink, led by Elon Musk and founded by Science CEO Max Hodak's former employer, has implanted its N1 device in 20+ patients as of mid-2026 and was valued at $9.7 billion in October 2025, far outpacing Science's $1.5 billion valuation.
- Could AI replace what Science Corporation does?
- No. Science's value sits in hardware, surgical implantation, and regulatory approvals like CE marking and FDA Breakthrough Device status for PRIMA, granted by July 22, 2026, none of which AI can substitute; AI could only touch adjacent signal-decoding software layers.
- Who owns Science Corporation?
- Science is privately held, founded in 2021 and led by CEO Max Hodak, co-founder and former president of Neuralink. Its Series C, announced March 5, 2026, was led by Lightspeed Venture Partners with Khosla Ventures, Y Combinator, Quiet Capital, and IQT participating.
- How much money has Science Corporation raised?
- Science closed a $230 million Series C on March 5, 2026, at a $1.5 billion post-money valuation, bringing total funding to approximately $490 million since its 2021 founding, according to the company's own March 4, 2026 announcement.
Timeline
- 2026-07-23Coverage confirms European rollout of PRIMA and NEJM trial data of 38 patients across 17 sites, 5 countries
- 2026-07-22PRIMA receives CE marking, launches commercially across 30 European countries, zero revenue reported yet
- 2026-04-14Yale neurosurgery chair Murat Günel enlisted to lead first US human trials of biohybrid brain sensor
- 2026-03-05Science closes $230M Series C led by Lightspeed, valuation reaches $1.5B, headcount ~150
- 2026-03-04Company reports total funding since 2021 reaches approximately $490 million
- 2025-12Hodak publicly claims PRIMA showed first definitive restoration of fluent reading in blind patients
- 2024-04-25Science acquires Pixium Vision's PRIMA retinal implant IP and related assets
- 2024-02-02Pixium Vision's sale plan rejected by court, converted to liquidation proceedings
- 2021Science Corporation founded in Alameda, California by Max Hodak and co-founders
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Science Corp. closes $230M Series C to support BCI tech (2026-03-05)
- Science Corp. raises $230M as it races to bring its brain implant to market (2026-03-05)
- Science Corp. raises $230M as it races to bring its brain implant to market (2026-03-05)
- Science Closes $230 Million Series C to Fund Commercialization of PRIMA (2026-03-04)
- Science Corporation begins European rollout of Prima system (2026-07-23)
- Science Corp. Announces European Commercial Launch of PRIMA (2026-07-22)
- Science Corp. launches Prima vison-restoring BCI in Europe (2026-07-22)
- Max Hodak's Science Corp. is preparing to place its first sensor in a human brain (2026-04-14)
- Science Corp prepares first human brain sensor placement with Yale neurosurgeon (2026-05-06)
- Billionaires (and a Trillionaire) Race to Create Cyborgs (2026-07-09)
- 5 Startups Wiring the Future of Human-Computer Interaction (2025-10-28)
- Precision Neuro breaks new ground in BCI technology (2026-07-23)